Shots: The collaboration focuses on advancing modular production in the industry. A first state-of-the-art, modular plant in the production environment is to be built at the Darmstadt site of Merck […]readmore
Tags : Sign
Shots: The companies collaborate with the Yangtze to commercialize eight biosimilars in China. The initial pipeline contains biosimilar candidates for the treatment of autoimmunity, ophthalmology, and oncology Alvotech and Alvotech […]readmore
Shots: The two global companies will supply up to ~60M doses of a vaccine to the UK’s government to combat COVID-19 Sanofi leads the clinical development and registration of the […]readmore
Shots: Sanofi and MD Anderson collaborated for 5yrs. to ramp up the development of investigational treatments, including targeted and immune-therapies for oncology patients. The alliance will support investigations into additional […]readmore
Shots: COVID Advocacy Exchange is a virtual platform targeted to unite patient advocacy organizations, patients, policy makers, healthcare practitioners and industry in the exchange of information and will also provide […]readmore
Shots: oNKo-innate to receive an up front, clinical, regulatory & commercial milestones along with royalties on sales of immuno-oncology and cell therapy programs while in exchange, the company will utilize […]readmore
The partnership will address the false and misleading promotion about biosimilars within their respective authorities and prevent anti-competitive behavior. Additionally, the agencies will collaborate with participants from industry, academia and […]readmore
Shots: CRISPR to gain access to KSQ intellectual property (IP) for editing certain novel gene targets in its allogeneic oncology cell therapy programs while KSQ will get access to CRISPR’ […]readmore
Shots: Bayer, BMS and Ono collaborate to evaluate the combination of Bayer’s Stivarga (regorafenib) with BMS & Ono’s Opdivo (nivolumab) vs regorafenib in patients with micro-satellite stable mCRC The collaboration […]readmore
Shots: Janssen to get exclusive WW license rights to develop & commercialize certain clinical candidates in MeiraGTx’s inherited retinal disease pipeline. Janssen also has an option to license the portfolio […]readmore